Languages
English
Japanese
Home
>
About Markit
>
Markit Updates
>
Letters to Regulatory Bodies
>
Letters to Regulatory Bodies 2009
Markit Updates
Commentary
Letters to Regulatory Bodies
Markit Newsletters
Letters to Regulatory Bodies - 2009
October
CEBS CP28 - Consultation Paper on Liquidity Buffers & Survival Periods
27 October 2009
Exposure Draft Improving Disclosures about Fair Value Measurements
12 October 2009
September
Consultation Paper Classification and identification of OTC derivative instruments for the purpose of the exchange of transaction reports amongst CESR Members
30 September 2009
IASB Exposure Drafts Financial Instruments: Classification and Measurement and Fair Value Measurement
10 September 2009
August
Consultation Document: Possible initiatives to enhance the resilience of OTC
31 August 2009
April
IASB Request for Views on FASB Staff Positions FAS 157-4 and FAS 115-2 dealing with guidance on fair value measurement and impairments of financial instruments
18 April 2009
ESCB/CESR Draft Recommendations for Central Counterparties as amended for OTC derivatives
16 April 2009
Proposed FASB Staff Position FAS 157-e: Determining Whether a Market Is Not Active and a Transaction Is not Distressed
01 April 2009
February
Transparency of corporate bond, structured finance product and credit derivatives markets
19 February 2009
Call for evidence on the technical standards to identify and classify OTC derivative instruments for TREM
19 February 2009
January
Consultation Paper on Strengthening Liquidity Standards
28 January 2009
Supervisory guidance for assessing banks' financial instrument fair value practices
19 January 2009
External audit quality and banking supervision
14 January 2009
Letters Archive
Letters to Regulatory Bodies - 2009
Letters to Regulatory Bodies - 2008
For more information about Markit, please contact us at any of our
regional offices
Home
Careers
Contact Us
Site Map
Copyright © Markit Group Limited. ALL DATA PROVIDED AS IS, WITH NO WARRANTIES. All rights reserved.
Data may not be reproduced or redistributed in any form, except as expressly authorized by Markit Group Limited.
Privacy Policy
Terms of Use
Feedback
Disclaimer